What is the 13F Pro Quality Score for AUPH?

13F Pro ranks Aurinia Pharmaceuticals Inc. (AUPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AUPH's current score at https://13fpro.ai/research/AUPH (free sign-up required for the full ranking).

Which hedge funds own the most AUPH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AUPH include TANG CAPITAL MANAGEMENT, BlackRock,, NEA Management Company,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AUPH as soon as new 13F filings post.

Where does 13F Pro source AUPH data?

All Aurinia Pharmaceuticals Inc. fundamentals and ownership data come directly from SEC EDGAR. Aurinia Pharmaceuticals Inc. files with the SEC under CIK 1600620. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AUPH in?

Aurinia Pharmaceuticals Inc. (AUPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AUPH research updated on 13F Pro?

AUPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aurinia Pharmaceuticals Inc.(AUPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1600620 AUPH stock profile & AI dashboard →

13F Pro Quality Score

73.3/100

Rank #200 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.9/100

Profitability

94.1/100

Balance Sheet

92.9/100

Earnings Quality

30.0/100

Free Cash Flow

91.1/100

Institutional Flow

55.4/100

Revenue Scale

28.8/100

Dilution Risk

25.3/100

AUPH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Aurinia Pharmaceuticals Inc. (AUPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUPH at 73.3/100 on a 32-signal composite quality model, placing it at rank #200 of 2,879 stocks — the top 10% of the AI-ranked universe. AUPH scores in the top quartile across profitability (94.1), balance sheet strength (92.9), free cash flow (91.1). Areas of concern include revenue scale (28.8) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Aurinia Pharmaceuticals Inc. reports quarterly revenue of $77.7M, net income of $34.4M, an operating margin of 53.3%. Top institutional holders of AUPH by reported 13-F value include TANG CAPITAL MANAGEMENT, BlackRock,, NEA Management Company,, based on the most recent SEC filings. AUPH trades on the Nasdaq exchange and files with the SEC under CIK 1600620. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aurinia Pharmaceuticals Inc. directly from SEC EDGAR. Aurinia Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 8 and 80 since 2021, currently 73.3 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Aurinia Pharmaceuticals Inc.

Quirks, history, and lore behind AUPH — the kind of stuff that makes a stock memorable.

1
The Basics
A Canadian biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in British Columbia.
2
The Numbers
Revenue in the tens of millions of dollars annually, funded heavily by its first commercial product — the kind of revenue profile that keeps biotech investors nervously refreshing their brokerage apps.
3
The History
The company spent years in clinical development before winning FDA approval in 2021 for its lead drug — a milestone that turned a research-stage company into a commercial one almost overnight.
4
The Secret
Its entire commercial bet is on a single oral drug targeting lupus nephritis, a serious autoimmune kidney disease with very few approved treatment options.
5
The Lore
The approved drug, voclosporin, works by inhibiting calcineurin — a mechanism borrowed from transplant medicine and retuned specifically for lupus kidney inflammation.
6
The Giveaway
One drug, one disease, one very niche corner of nephrology: their flagship product Lupkynis is the first oral calcineurin inhibitor ever approved specifically for lupus nephritis.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$77.7M

Net Income

Q1 2026

$34.4M

Free Cash Flow

Q1 2026

$32.6M

Operating Margin

Q1 2026

53.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.4% YoY

$283.1MFY 2025

FY22 $134.0MFY23 $175.5MFY24 $235.1MFY25 $283.1M

Net Income

+4851.8% YoY

$287.2MFY 2025

FY22 $-108.2MFY23 $-78.0MFY24 $5.8MFY25 $287.2M

Operating Income

+2338.4% YoY

$104.9MFY 2025

FY22 $-111.5MFY23 $-91.7MFY24 $-4.7MFY25 $104.9M

EPS (Diluted)

+5075.0% YoY

$2.07FY 2025

FY22 $-0.76FY23 $-0.54FY24 $0.04FY25 $2.07

Total Assets

+36.5% YoY

$751.6MFY 2025

FY22 $470.9MFY23 $548.1MFY24 $550.6MFY25 $751.6M

Op. Cash Flow

+205.6% YoY

$135.7MFY 2025

FY22 $-79.5MFY23 $-33.5MFY24 $44.4MFY25 $135.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$283.1M +20.4%	$235.1M +34.0%	$175.5M +31.0%	$134.0M +193.9%	$45.6M -9.0%	$50.1M
Net Income	$287.2M +4851.8%	$5.8M +107.4%	$-78.0M +27.9%	$-108.2M +40.2%	$-181.0M -76.3%	$-102.7M
Operating Income	$104.9M +2338.4%	$-4.7M +94.9%	$-91.7M +17.7%	$-111.5M +38.3%	$-180.7M -73.3%	$-104.3M
EPS (Diluted)	$2.07 +5075.0%	$0.04 +107.4%	$-0.54 +28.9%	$-0.76 +45.7%	$-1.40 -60.9%	$-0.87
Total Assets	$751.6M +36.5%	$550.6M +0.5%	$548.1M +16.4%	$470.9M -13.3%	$543.4M +17.2%	$463.7M
Operating Cash Flow	$135.7M +205.6%	$44.4M +232.7%	$-33.5M +57.9%	$-79.5M +49.6%	$-157.7M -125.7%	$-69.9M

Get alerted when AUPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aurinia Pharmaceuticals Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AUPH

TANG CAPITAL MANAGEMENT LLC
$181.2M12,229,500 sh
BlackRock, Inc.
$116.3M7,845,521 sh
NEA Management Company, LLC
$58.8M3,969,834 sh
TWO SIGMA INVESTMENTS, LP
$50.8M3,428,705 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$48.7M3,284,368 sh
STATE STREET CORP
$37.5M2,527,099 sh
MORGAN STANLEY
$33.1M2,232,548 sh
MARSHALL WACE, LLP
$27.8M1,874,597 sh
RENAISSANCE TECHNOLOGIES LLC
$24.7M1,663,835 sh
D. E. Shaw & Co., Inc.
$23.3M1,572,983 sh

Fund	Value	Shares
TANG CAPITAL MANAGEMENT LLC	$181.2M	12,229,500
BlackRock, Inc.	$116.3M	7,845,521
NEA Management Company, LLC	$58.8M	3,969,834
TWO SIGMA INVESTMENTS, LP	$50.8M	3,428,705
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$48.7M	3,284,368
STATE STREET CORP	$37.5M	2,527,099
MORGAN STANLEY	$33.1M	2,232,548
MARSHALL WACE, LLP	$27.8M	1,874,597
RENAISSANCE TECHNOLOGIES LLC	$24.7M	1,663,835
D. E. Shaw & Co., Inc.	$23.3M	1,572,983

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AUPH on your watchlist

Track score changes the day Aurinia Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AUPH a good stock to buy?

13F Pro's AI-powered analysis of Aurinia Pharmaceuticals Inc. (AUPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AUPH are available on the AUPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AUPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AUPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aurinia Pharmaceuticals Inc.'s investment landscape.